Filing Flows › Protalix BioTherapeutics (PLX) › Q1 2026 › vs Q1 2025
Protalix BioTherapeutics (PLX) Q1 2026 vs Q1 2025 (year over year)
Protalix BioTherapeutics's revenue rose $23.6M (+234%) from $10.1M in Q1 2025 to $33.8M in Q1 2026. The biggest changes: LICENSE AND R&D SERVICES +$26.2M (223×); GOODS −$2.6M (-26%). Operating margin 62.7% against -41.0% (+103.6 pts).
Protalix BioTherapeutics, Q1 2026: revenue $33.8M (+234% year over year), operating margin 62.7%, net earnings $18.3M, operating cash flow $22.0M. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Operating margin | 62.7% | -41.0% | +103.6 pts |
| Net margin | 54.3% | -35.8% | +90.1 pts |
| Free cash flow margin | 63.0% | -53.0% | +116.0 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| LICENSE AND R&D SERVICES | $26.3M | $118K | $26.2M | 223× |
| GOODS | $7.4M | $10.0M | −$2.6M | -26% |
| Revenue | $33.8M | $10.1M | $23.6M | +234% |
| Operating profit | $21.1M | −$4.1M | $25.3M | — |
| Costs & expenses | $12.6M | $14.3M | −$1.7M | -12% |
| Pre-tax earnings | $21.1M | −$3.7M | $24.9M | — |
| Cost of revenue | $4.1M | $8.2M | −$4.1M | -50% |
| Research & development | $5.4M | $3.5M | $2.0M | +56% |
| SG&A | $3.1M | $2.6M | $448K | +17% |
| Net earnings | $18.3M | −$3.6M | $21.9M | — |
| Income tax | $2.8M | −$113K | $2.9M | — |
| Depreciation | $404K | $346K | $58K | +17% |
| Share-based compensation | $532K | $540K | −$8K | -1% |
| Working capital & other | $2.8M | −$2.3M | $5.1M | — |
| Operating cash flow | $22.0M | −$5.1M | $27.1M | — |
| Free cash flow (OCF − capex) | $21.3M | −$5.4M | $26.6M | — |
| Capital expenditures | $761K | $306K | $455K | +149% |
Questions
How much did Protalix BioTherapeutics's revenue grow year over year in Q1 2026?
Protalix BioTherapeutics's revenue rose $23.6M (+234%) from $10.1M in Q1 2025 to $33.8M in Q1 2026.
What drove Protalix BioTherapeutics's revenue change in Q1 2026?
LICENSE AND R&D SERVICES +$26.2M (223×); GOODS −$2.6M (-26%).